Pyrimidone Carboxamide PDE2 Inhibitors for Cognitive Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for schizophrenia are inadequate due to low efficacy and severe side effects, and there is a need for new modulators that can effectively target phosphodiesterase 2 (PDE2) to address cognitive impairment, depression, migraines, and other neurological disorders.
Innovation Solution
Development of pyrimidone carboxamide compounds that act as selective inhibitors of PDE2, which can be used to treat central nervous system and peripheral disorders such as schizophrenia, anxiety, depression, migraines, and Huntington's disease by increasing cAMP and/or cGMP levels in neurons.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antipsychotic treatments (typical and atypical) are used, then psychotic symptoms are addressed, but severe side effects occur including metabolic, extrapyramidal, prolactic and cardiac adverse events
Solution Approach 1:
The patent changes the pharmacological parameter by targeting a different enzyme (PDE2) with a different mechanism of action compared to conventional antipsychotics. The pyrimidone carboxamide compounds modify the biochemical parameter of cGMP degradation, leading to increased cGMP levels and improved cognitive function without the dopamine receptor blockade that causes extrapyramidal side effects
Solution Approach 2:
The patent extracts and addresses only the cognitive impairment aspect of schizophrenia by selectively inhibiting PDE2, rather than using broad-spectrum antipsychotics that affect multiple pathways. This selective approach removes the unnecessary side effects while maintaining therapeutic benefit for cognitive symptoms
2Object-affected harmful factors
If selective PDE2 inhibitors are developed, then cognitive function is improved with reduced side effects, but new compound development and validation is required
Solution Approach 1:
The patent segments the complex task of treating schizophrenia into a specific target (PDE2 enzyme) and develops compounds with selective affinity for this target. The pyrimidone carboxamide structure is designed to specifically inhibit PDE2, separating the cognitive benefit from the side effect profile of conventional antipsychotics
Solution Approach 2:
The patent changes the chemical parameter space by developing a novel pyrimidone carboxamide scaffold with specific structural features (substituents at positions 5 and 6 of the pyrimidone ring) that confer selective PDE2 inhibition. This structural parameter optimization enables high selectivity and potency while minimizing off-target effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The pyrimidone carboxamide compounds effectively inhibit PDE2, potentially offering improved therapeutic outcomes for schizophrenia and other neurological disorders with reduced side effects by enhancing cognitive function and addressing various neurological and psychiatric conditions.
Implementation Method 1
pyrimidone carboxamide compounds which act as selective inhibitors of PDE2... effectively inhibit PDE2... increasing cAMP and/or cGMP levels in neurons
Data Source
AI summary
Disclosed are pyrimidine carboxamide compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2), pharmaceutical compositions and uses thereof.